Journal article · 2026 · Open access

Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement?

Sam Schoenmakers, C. J. G. Bakker, Alexandra Ganev, Florence Butlen‐Ducuing, Corinne S de Vries

Clinical Pharmacology & Therapeutics · Published 22 October 2026 · DOI 10.1002/cpt.70529

Open PDFView at the publisherCite this paper

In brief

“Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement?” is a 2026 journal article by Sam Schoenmakers and 4 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 1 citations as of 17 November 2026, which puts it in the top 9% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Clinical Pharmacology & Therapeutics.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
4.48
References
35
Authors
5

Abstract

Pregnant and breastfeeding individuals are routinely excluded from clinical drug development, creating persistent evidence gaps in pharmacology, safety, and dosing. Despite mandatory contraception and pregnancy testing, unintended pregnancies occur, particularly during the development of central nervous system (CNS) medicines used by women of reproductive age. Once exposure to an investigational medicinal product (IMP) has occurred, these pregnancies may provide valuable prospective human data; however, treatment or trial participation is often discontinued and follow-up may be incomplete. This study assessed how unintended pregnancies and breastfeeding data were reported, managed, and evaluated in clinical trials supporting marketing authorization applications (MAAs) for CNS products. We reviewed 35 MAAs for centrally authorized CNS products submitted to the European Medicines Agency between 2012 and 2022. Pregnancy frequency, IMP exposure, pregnancy outcomes, breastfeeding data and regulatory comments were extracted from MAA dossiers, Day 120 Lists of Questions and Summaries of Product Characteristics. Overall, 451 pregnancies were identified, including 343 with IMP exposure. Of these, 108 occurred in pivotal phase 3 trials, resulting in 39 live births, 23 elective terminations, 17 spontaneous pregnancy losses, and 29 unknown or ongoing outcomes. Regulators raised 19 pregnancy-related and six breastfeeding-related concerns. Only one dossier included a dedicated human lactation study. Pregnancy reporting varied substantially in location, format and case-level detail, while 27% of pivotal IMP-exposed pregnancies had unknown or ongoing outcomes at assessment. More structured reporting and follow-up, including relevant exposure and pharmacokinetic data where feasible, could strengthen clinical pharmacology and regulatory evidence and support more informative product information.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Schoenmakers, S., Bakker, C. J. G., Ganev, A., Butlen‐Ducuing, F., & de Vries, C. S. (2026). Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement? Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70529

MLA 9

Schoenmakers, Sam, et al. “Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement?” Clinical Pharmacology & Therapeutics, 2026. https://doi.org/10.1002/cpt.70529.

Chicago

Schoenmakers, Sam, C. J. G. Bakker, Alexandra Ganev, Florence Butlen‐Ducuing, and Corinne S de Vries. 2026. “Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement?” Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70529.

Harvard

Schoenmakers, S. et al. (2026) ‘Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement?’, Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.70529.

IEEE

S. Schoenmakers, C. J. G. Bakker, A. Ganev, F. Butlen‐Ducuing, and C. S. de Vries, “Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement?,” Clinical Pharmacology & Therapeutics, 2026, doi: 10.1002/cpt.70529.

BibTeX

@article{schoenmakers2026unintended,
  title     = {{Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement?}},
  author    = {Schoenmakers, Sam and Bakker, C. J. G. and Ganev, Alexandra and Butlen‐Ducuing, Florence and de Vries, Corinne S},
  journal   = {Clinical Pharmacology \& Therapeutics},
  year      = {2026},
  doi       = {10.1002/cpt.70529},
  url       = {https://doi.org/10.1002/cpt.70529}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact

  • unintended pregnancy
  • breastfeeding
  • central nervous system drugs
  • clinical development
  • prenatal exposure
  • marketing authorization applications
  • regulatory reporting
  • pregnancy outcomes

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Schoenmakers, S., Bakker, C. J. G., Ganev, A., Butlen‐Ducuing, F., & de Vries, C. S. (2026). Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement? Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70529

How many times has this paper been cited?

1 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.

Who wrote this paper?

Sam Schoenmakers, C. J. G. Bakker, Alexandra Ganev, Florence Butlen‐Ducuing, Corinne S de Vries.

What is the DOI of this paper?

10.1002/cpt.70529, permanently at https://doi.org/10.1002/cpt.70529. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.